| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 48 | 2025 | 281 | 13.870 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 38 | 2025 | 206 | 8.300 |
Why?
|
| Pulmonary Fibrosis | 18 | 2024 | 149 | 5.960 |
Why?
|
| Alveolitis, Extrinsic Allergic | 11 | 2024 | 43 | 2.690 |
Why?
|
| Lung | 21 | 2024 | 1337 | 2.400 |
Why?
|
| Mucin-5B | 5 | 2024 | 12 | 2.390 |
Why?
|
| Tomography, X-Ray Computed | 17 | 2024 | 2680 | 1.980 |
Why?
|
| Lung Transplantation | 6 | 2024 | 350 | 1.830 |
Why?
|
| Autoimmune Diseases | 4 | 2024 | 252 | 1.430 |
Why?
|
| Connective Tissue Diseases | 10 | 2024 | 70 | 1.420 |
Why?
|
| Telomere | 8 | 2024 | 119 | 1.350 |
Why?
|
| Humans | 99 | 2025 | 92337 | 1.240 |
Why?
|
| Disease Progression | 14 | 2024 | 1503 | 1.190 |
Why?
|
| Pyridones | 2 | 2020 | 58 | 1.160 |
Why?
|
| Aged | 46 | 2025 | 19943 | 1.100 |
Why?
|
| Registries | 8 | 2024 | 902 | 1.070 |
Why?
|
| Indoles | 2 | 2020 | 306 | 1.050 |
Why?
|
| Hospitalization | 5 | 2024 | 927 | 1.030 |
Why?
|
| Cohort Studies | 19 | 2025 | 2978 | 1.020 |
Why?
|
| Idiopathic Interstitial Pneumonias | 4 | 2022 | 28 | 1.020 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 1 | 2024 | 4 | 0.920 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2024 | 10 | 0.920 |
Why?
|
| Machine Learning | 2 | 2024 | 298 | 0.910 |
Why?
|
| Male | 54 | 2025 | 43925 | 0.890 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2024 | 178 | 0.860 |
Why?
|
| Fibrosis | 6 | 2023 | 239 | 0.860 |
Why?
|
| Predictive Value of Tests | 5 | 2024 | 1763 | 0.830 |
Why?
|
| Emphysema | 1 | 2023 | 22 | 0.830 |
Why?
|
| Middle Aged | 42 | 2025 | 27030 | 0.820 |
Why?
|
| Pulmonary Emphysema | 1 | 2023 | 39 | 0.820 |
Why?
|
| Nitric Oxide | 2 | 2022 | 283 | 0.800 |
Why?
|
| Immunosuppressive Agents | 7 | 2024 | 989 | 0.800 |
Why?
|
| Retrospective Studies | 27 | 2025 | 9703 | 0.780 |
Why?
|
| Prognosis | 13 | 2025 | 3872 | 0.780 |
Why?
|
| Female | 51 | 2025 | 47893 | 0.780 |
Why?
|
| Delayed Diagnosis | 2 | 2019 | 39 | 0.770 |
Why?
|
| Mediastinum | 2 | 2019 | 48 | 0.770 |
Why?
|
| Autoimmunity | 4 | 2018 | 175 | 0.760 |
Why?
|
| Rheumatoid Factor | 1 | 2021 | 26 | 0.760 |
Why?
|
| Mediastinal Diseases | 1 | 2021 | 22 | 0.750 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2024 | 351 | 0.750 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 20 | 0.740 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2023 | 131 | 0.740 |
Why?
|
| Intra-Abdominal Fat | 1 | 2021 | 33 | 0.730 |
Why?
|
| Friends | 1 | 2021 | 20 | 0.720 |
Why?
|
| Genomics | 2 | 2024 | 806 | 0.710 |
Why?
|
| Radiography, Thoracic | 3 | 2019 | 332 | 0.680 |
Why?
|
| Precision Medicine | 1 | 2024 | 425 | 0.660 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2020 | 52 | 0.660 |
Why?
|
| Hypertension, Pulmonary | 5 | 2022 | 376 | 0.650 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2020 | 217 | 0.650 |
Why?
|
| Mortality | 1 | 2020 | 150 | 0.640 |
Why?
|
| Respiratory Function Tests | 7 | 2024 | 145 | 0.640 |
Why?
|
| Racism | 1 | 2021 | 96 | 0.640 |
Why?
|
| Vital Capacity | 6 | 2024 | 69 | 0.610 |
Why?
|
| Proportional Hazards Models | 8 | 2025 | 871 | 0.610 |
Why?
|
| Patient Compliance | 1 | 2020 | 236 | 0.600 |
Why?
|
| Lymph Nodes | 2 | 2019 | 552 | 0.590 |
Why?
|
| Biomarkers | 7 | 2024 | 1850 | 0.570 |
Why?
|
| Pandemics | 2 | 2021 | 812 | 0.570 |
Why?
|
| Betacoronavirus | 1 | 2020 | 269 | 0.550 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 291 | 0.550 |
Why?
|
| Pathology, Clinical | 1 | 2017 | 36 | 0.540 |
Why?
|
| Multiple Chronic Conditions | 1 | 2016 | 6 | 0.530 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2025 | 2394 | 0.500 |
Why?
|
| United States | 12 | 2024 | 7348 | 0.500 |
Why?
|
| Proteomics | 4 | 2024 | 246 | 0.490 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 328 | 0.480 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 313 | 0.480 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 827 | 0.470 |
Why?
|
| Inflammation | 2 | 2024 | 1025 | 0.460 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 246 | 0.450 |
Why?
|
| Respiratory Insufficiency | 1 | 2016 | 183 | 0.440 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2015 | 107 | 0.440 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2015 | 151 | 0.430 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 652 | 0.420 |
Why?
|
| Prevalence | 8 | 2024 | 1294 | 0.400 |
Why?
|
| Survival Analysis | 5 | 2024 | 1511 | 0.390 |
Why?
|
| Leukocytes | 3 | 2023 | 212 | 0.390 |
Why?
|
| Aortic Valve Stenosis | 2 | 2011 | 157 | 0.390 |
Why?
|
| Minority Groups | 2 | 2023 | 150 | 0.380 |
Why?
|
| Risk Assessment | 6 | 2021 | 2369 | 0.370 |
Why?
|
| Aging | 2 | 2025 | 738 | 0.330 |
Why?
|
| Hypoxia | 1 | 2015 | 672 | 0.330 |
Why?
|
| Referral and Consultation | 2 | 2024 | 353 | 0.310 |
Why?
|
| Environmental Exposure | 2 | 2025 | 340 | 0.300 |
Why?
|
| Survival Rate | 4 | 2020 | 1927 | 0.300 |
Why?
|
| Adult | 14 | 2025 | 27532 | 0.290 |
Why?
|
| Quality of Life | 1 | 2016 | 1744 | 0.290 |
Why?
|
| Prospective Studies | 7 | 2024 | 4468 | 0.280 |
Why?
|
| Cause of Death | 2 | 2019 | 270 | 0.280 |
Why?
|
| Echocardiography | 2 | 2022 | 968 | 0.280 |
Why?
|
| Delphi Technique | 2 | 2024 | 105 | 0.270 |
Why?
|
| Genome-Wide Association Study | 3 | 2023 | 1723 | 0.260 |
Why?
|
| Biology | 2 | 2023 | 52 | 0.250 |
Why?
|
| Promoter Regions, Genetic | 2 | 2019 | 968 | 0.250 |
Why?
|
| Clinical Decision-Making | 2 | 2025 | 291 | 0.250 |
Why?
|
| Postoperative Complications | 1 | 2016 | 2458 | 0.240 |
Why?
|
| Heart Failure | 1 | 2015 | 1346 | 0.240 |
Why?
|
| Acute Chest Syndrome | 1 | 2025 | 24 | 0.230 |
Why?
|
| Severity of Illness Index | 3 | 2024 | 1919 | 0.230 |
Why?
|
| Eligibility Determination | 1 | 2024 | 36 | 0.230 |
Why?
|
| Particulate Matter | 1 | 2025 | 104 | 0.220 |
Why?
|
| Triage | 1 | 2025 | 125 | 0.220 |
Why?
|
| Phenotype | 3 | 2020 | 2498 | 0.210 |
Why?
|
| Diagnosis, Differential | 5 | 2024 | 1592 | 0.210 |
Why?
|
| Risk Factors | 4 | 2024 | 5704 | 0.210 |
Why?
|
| Scleroderma, Systemic | 1 | 2024 | 57 | 0.210 |
Why?
|
| Telomerase | 2 | 2020 | 68 | 0.210 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2023 | 54 | 0.210 |
Why?
|
| Tobacco Smoking | 1 | 2023 | 30 | 0.210 |
Why?
|
| Reference Values | 1 | 2024 | 660 | 0.210 |
Why?
|
| Oxygen | 2 | 2025 | 763 | 0.210 |
Why?
|
| Pseudomonas Infections | 1 | 2023 | 101 | 0.210 |
Why?
|
| Biopsy | 4 | 2021 | 1194 | 0.200 |
Why?
|
| Age Factors | 3 | 2020 | 1905 | 0.200 |
Why?
|
| Consensus | 1 | 2024 | 376 | 0.200 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 174 | 0.200 |
Why?
|
| Patient Readmission | 2 | 2024 | 393 | 0.200 |
Why?
|
| Shock, Septic | 1 | 2023 | 108 | 0.200 |
Why?
|
| Survivors | 1 | 2023 | 199 | 0.190 |
Why?
|
| Longitudinal Studies | 3 | 2022 | 1119 | 0.180 |
Why?
|
| Sex Factors | 2 | 2024 | 1095 | 0.180 |
Why?
|
| Azathioprine | 2 | 2023 | 124 | 0.180 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2021 | 102 | 0.180 |
Why?
|
| Respiratory Mucosa | 1 | 2021 | 88 | 0.180 |
Why?
|
| Inhalation Exposure | 1 | 2021 | 31 | 0.180 |
Why?
|
| Health Services | 1 | 2021 | 57 | 0.180 |
Why?
|
| Epigenesis, Genetic | 1 | 2025 | 538 | 0.180 |
Why?
|
| Occupational Health | 1 | 2021 | 36 | 0.170 |
Why?
|
| Hematology | 1 | 2020 | 30 | 0.170 |
Why?
|
| Time Factors | 4 | 2024 | 5430 | 0.170 |
Why?
|
| Patient Selection | 1 | 2024 | 689 | 0.170 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2020 | 389 | 0.170 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 77 | 0.170 |
Why?
|
| Treatment Outcome | 3 | 2024 | 8740 | 0.170 |
Why?
|
| Telomere-Binding Proteins | 1 | 2019 | 14 | 0.160 |
Why?
|
| Occupational Exposure | 1 | 2021 | 88 | 0.160 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 277 | 0.160 |
Why?
|
| Myeloblastin | 1 | 2019 | 5 | 0.160 |
Why?
|
| Mutation | 3 | 2020 | 4204 | 0.160 |
Why?
|
| Peroxidase | 1 | 2019 | 53 | 0.160 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2019 | 22 | 0.160 |
Why?
|
| Comorbidity | 3 | 2024 | 987 | 0.160 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2024 | 278 | 0.150 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 996 | 0.150 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 378 | 0.150 |
Why?
|
| Genotype | 2 | 2022 | 1863 | 0.150 |
Why?
|
| Influenza, Human | 1 | 2021 | 343 | 0.140 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 130 | 0.140 |
Why?
|
| Free Radical Scavengers | 1 | 2018 | 60 | 0.140 |
Why?
|
| Anticoagulants | 1 | 2021 | 443 | 0.140 |
Why?
|
| Bronchiectasis | 1 | 2017 | 14 | 0.140 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 451 | 0.140 |
Why?
|
| Acetylcysteine | 1 | 2018 | 71 | 0.140 |
Why?
|
| Propensity Score | 1 | 2018 | 165 | 0.140 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2017 | 18 | 0.140 |
Why?
|
| Interleukin-5 | 1 | 2017 | 36 | 0.140 |
Why?
|
| Chronic Disease | 2 | 2017 | 963 | 0.140 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 3775 | 0.140 |
Why?
|
| Cell Differentiation | 1 | 2023 | 1592 | 0.130 |
Why?
|
| Cluster Analysis | 1 | 2017 | 376 | 0.130 |
Why?
|
| Acute Lung Injury | 1 | 2017 | 66 | 0.130 |
Why?
|
| Disease Management | 2 | 2016 | 340 | 0.130 |
Why?
|
| Cytokines | 2 | 2023 | 843 | 0.130 |
Why?
|
| Pulmonary Alveoli | 1 | 2016 | 72 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 2447 | 0.130 |
Why?
|
| Transcriptome | 1 | 2021 | 699 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 619 | 0.120 |
Why?
|
| Aged, 80 and over | 3 | 2024 | 6916 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 2 | 2024 | 1079 | 0.120 |
Why?
|
| Chemotactic Factors | 1 | 2015 | 14 | 0.120 |
Why?
|
| Hypoventilation | 1 | 2015 | 6 | 0.120 |
Why?
|
| STAT6 Transcription Factor | 1 | 2015 | 28 | 0.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 95 | 0.120 |
Why?
|
| Carrier Proteins | 1 | 2018 | 680 | 0.120 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 108 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2017 | 476 | 0.120 |
Why?
|
| Antigens | 1 | 2016 | 228 | 0.120 |
Why?
|
| Logistic Models | 1 | 2018 | 1239 | 0.110 |
Why?
|
| rho-Associated Kinases | 1 | 2015 | 162 | 0.110 |
Why?
|
| Sleep Wake Disorders | 1 | 2015 | 121 | 0.110 |
Why?
|
| Hematologic Neoplasms | 1 | 2017 | 355 | 0.110 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 469 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 328 | 0.100 |
Why?
|
| Case-Control Studies | 3 | 2024 | 1902 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2015 | 282 | 0.100 |
Why?
|
| Animals | 3 | 2024 | 28003 | 0.100 |
Why?
|
| Canada | 2 | 2023 | 205 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2015 | 466 | 0.100 |
Why?
|
| Child | 1 | 2023 | 7334 | 0.090 |
Why?
|
| Sensitivity and Specificity | 3 | 2024 | 2009 | 0.090 |
Why?
|
| Autopsy | 2 | 2021 | 123 | 0.090 |
Why?
|
| Signal Transduction | 2 | 2020 | 3508 | 0.070 |
Why?
|
| Antibodies, Antinuclear | 2 | 2018 | 87 | 0.070 |
Why?
|
| Obesity | 1 | 2015 | 1016 | 0.070 |
Why?
|
| Cell Cycle Proteins | 2 | 2020 | 403 | 0.070 |
Why?
|
| Chicago | 2 | 2024 | 1466 | 0.060 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2011 | 523 | 0.060 |
Why?
|
| British Columbia | 1 | 2025 | 10 | 0.060 |
Why?
|
| Genetic Variation | 2 | 2025 | 1392 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 2394 | 0.060 |
Why?
|
| Oximetry | 1 | 2025 | 87 | 0.060 |
Why?
|
| Mexico | 1 | 2024 | 71 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 866 | 0.060 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2024 | 130 | 0.060 |
Why?
|
| Blood Proteins | 1 | 2024 | 149 | 0.050 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2023 | 19 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2024 | 207 | 0.050 |
Why?
|
| Proprotein Convertases | 1 | 2023 | 26 | 0.050 |
Why?
|
| Rituximab | 1 | 2024 | 123 | 0.050 |
Why?
|
| Monocytes | 1 | 2024 | 223 | 0.050 |
Why?
|
| Carbon Monoxide | 1 | 2023 | 93 | 0.050 |
Why?
|
| Australasia | 1 | 2023 | 4 | 0.050 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2023 | 48 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2024 | 304 | 0.050 |
Why?
|
| Lung Volume Measurements | 1 | 2022 | 21 | 0.050 |
Why?
|
| Serine Endopeptidases | 1 | 2023 | 146 | 0.050 |
Why?
|
| Europe | 1 | 2023 | 328 | 0.050 |
Why?
|
| North America | 1 | 2023 | 188 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2025 | 429 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2794 | 0.050 |
Why?
|
| Emergency Service, Hospital | 1 | 2025 | 559 | 0.040 |
Why?
|
| In Situ Hybridization | 1 | 2021 | 313 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2024 | 601 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2025 | 677 | 0.040 |
Why?
|
| Chitinase-3-Like Protein 1 | 1 | 2020 | 9 | 0.040 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2020 | 11 | 0.040 |
Why?
|
| CA-125 Antigen | 1 | 2020 | 22 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2020 | 7 | 0.040 |
Why?
|
| Chemokine CXCL13 | 1 | 2020 | 16 | 0.040 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2020 | 56 | 0.040 |
Why?
|
| Exoribonucleases | 1 | 2019 | 9 | 0.040 |
Why?
|
| Spindle Apparatus | 1 | 2020 | 65 | 0.040 |
Why?
|
| Seasons | 1 | 2021 | 241 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2020 | 358 | 0.040 |
Why?
|
| Vasculitis | 1 | 2019 | 39 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 64 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2019 | 85 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 444 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2022 | 456 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 209 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 339 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 810 | 0.040 |
Why?
|
| Bleomycin | 1 | 2017 | 103 | 0.030 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2016 | 25 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 1807 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2017 | 111 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 2729 | 0.030 |
Why?
|
| Mycophenolic Acid | 1 | 2016 | 85 | 0.030 |
Why?
|
| Th2 Cells | 1 | 2017 | 148 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2017 | 234 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1774 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 390 | 0.030 |
Why?
|
| Algorithms | 1 | 2024 | 1956 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 1312 | 0.030 |
Why?
|
| RNA | 1 | 2019 | 589 | 0.030 |
Why?
|
| Observer Variation | 1 | 2017 | 612 | 0.030 |
Why?
|
| Pulmonary Artery | 1 | 2017 | 330 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2019 | 734 | 0.030 |
Why?
|
| Radiographic Image Enhancement | 1 | 2016 | 465 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 446 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2017 | 2087 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2017 | 2902 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 2448 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 3360 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 2004 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 6624 | 0.010 |
Why?
|
| Mice | 1 | 2017 | 12110 | 0.010 |
Why?
|